Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356755 | 0.92 | CYP3A4 (0.66) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL724387 | 0.92 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL27575969 | 0.90 | CYP3A4 (0.52) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5712340 | 0.90 | CYP3A4 (0.57) | CYP3A4SLC7A5NLNHRH4HRH3 | |
| SCHEMBL22462180 | 0.89 | CYP3A4 (0.60) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL22462183 | 0.89 | CYP3A4 (0.60) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL163444 | 0.89 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL1537285 | 0.89 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28331180 | 0.87 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL21772061 | 0.87 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220192179-A1 | BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2022-06-23 | — | — | US | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| US-10022319-B2 | Stabilized antibody-containing liquid formulations | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-07-17 | — | — | US | claimed |
| EP-1805303-A2 | MUTANT POLYMERASES FOR SEQUENCING AND GENOTYPING | Li-Cor, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070048748-A1 | Mutant polymerases for sequencing and genotyping | LI-COR, INC. (US) | 2007-03-01 | — | — | US | claimed |
| WO-2006037064-A2 | MUTANT POLYMERASES FOR SEQUENCING AND GENOTYPING | LI-COR, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20020049301-A1 | Short peptides which selectively modulate the activity of serine/threonine kinases | THE CHILDREN'S MEDICAL CENTER CORP. (US) | 2002-04-25 | — | — | US | claimed |
| EP-0983346-A2 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES | The Children's Medical Center Corporation (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998053050-A2 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
| EP-4507726-A1 | STABLE HIGH CONCENTRATION ARGININE FORMULATIONS CONTAINING PD-1 ANTIBODY AND METHODS OF USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034257-A1 | STABLE HIGH CONCENTRATION ARGININE FORMULATIONS CONTAINING PD-1 ANTIBODY AND METHODS OF USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | US | disclosed |
| CN-119173272-A | Stable high concentration arginine formulations containing PD-1 antibodies and methods of use thereof | 百济神州瑞士有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3714902-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSORBATE | LEK PHARMACEUTICALS (SI) | 2024-08-28 | — | — | EP | disclosed |
| US-5597698-A | CORN PLANTS | MYCOGEN PLANT SCIENCE, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5409837-A | Sensitive to bipolaris maydis a fungal pathogen and insecticide methomyl, genetic engineered protein is toxin insensitive | MYCOGEN PLANT SCIENCE, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0550629-A1 | METAL ION MEDIATED RECEPTOR BINDING OF POLYPEPTIDE HORMONES | GENENTECH, INC. (US) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992003478-A1 | METAL ION MEDIATED RECEPTOR BINDING OF POLYPEPTIDE HORMONES | GENENTECH, INC. (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | CYP3A4 4776/4885SLC7A5 241/4885NLN 3841/4885 |
| US-20220192179-A1 | BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME | IGFBP1, IGFBP2, BCL2L1 | CYP3A4 2872/4885SLC7A5 1637/4885NLN 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.